About StemCells, Biomedicine, Diet Impact, Mental Health, Meditation,Viruses & Regenerative Medicine

[north40000]

http://ih.advfn.com/p.php?pid=nmona&article=71789942

Principal subject of PR is very early pre-clinical work of PSTI in connection with use of its PLX-PAD cells to treat DMD.


".......Pluristem Therapeutics Inc. is a leading developer of placenta-based cell therapy products. The Company has reported robust clinical trial data in multiple indications for its patented PLX (PLacental eXpanded) cells. The cells release a cocktail of therapeutic proteins in response to inflammation, ischemia, hematological disorders, and radiation damage. PLX cell products are grown using the Company's proprietary three-dimensional expansion technology. They are off-the-shelf, requiring no tissue matching prior to administration......."